# Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients

> **NCT00129961** · PHASE4 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 86 (actual)

## Conditions studied

- Skin Neoplasms
- Kidney Transplantation

## Interventions

- **DRUG:** sirolimus
- **DRUG:** cyclosporine or tacrolimus

## Key facts

- **NCT ID:** NCT00129961
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2012-04-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00129961

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00129961, "Study Evaluating the Effect of Sirolimus on Non-Melanoma Skin Cancer in Kidney Transplant Recipients". Retrieved via MORVS 2026-11-03 from https://api.morvs.ai/clinical/NCT00129961. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*